FY2028 Earnings Forecast for CryoPort Issued By KeyCorp

CryoPort, Inc. (NASDAQ:CYRX) – Analysts at KeyCorp issued their FY2028 EPS estimates for shares of CryoPort in a report released on Thursday, November 5th. KeyCorp analyst P. Knight expects that the company will post earnings of ($0.26) per share for the year. KeyCorp currently has an “Overweight” rating and a $20.00 price objective on the stock. The consensus estimate for CryoPort’s current full-year earnings is ($0.88) per share.

CryoPort (NASDAQ:CYRX) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.07). CryoPort had a negative net margin of 21.46% and a negative return on equity of 8.28%. The company had revenue of $50.22 million during the quarter, compared to the consensus estimate of $48.66 million.

A number of other equities analysts have also issued reports on the company. Weiss Ratings raised CryoPort from a “sell (d)” rating to a “hold (c-)” rating in a research note on Thursday, October 8th. BTIG Research boosted their price objective on CryoPort from $25.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. Guggenheim upped their price objective on CryoPort from $16.00 to $19.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Roth Capital reaffirmed a “buy” rating and set a $21.00 target price on shares of CryoPort in a research note on Friday, August 7th. Finally, Robert W. Baird set a $26.00 target price on CryoPort in a report on Tuesday, October 13th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $21.69.

CryoPort Price Performance

Shares of NASDAQ:CYRX opened at $20.10 on Friday. The stock has a market cap of $1.02 billion, a price-to-earnings ratio of -20.72 and a beta of 1.89. CryoPort has a 12 month low of $7.61 and a 12 month high of $21.78. The stock’s 50 day moving average price is $17.35 and its 200 day moving average price is $13.65.

Institutional Investors Weigh In On CryoPort

A number of institutional investors and hedge funds have recently modified their holdings of CYRX. Roubaix Capital LLC lifted its stake in CryoPort by 12.4% during the third quarter. Roubaix Capital LLC now owns 454,926 shares of the company’s stock valued at $7,916,000 after buying an additional 50,148 shares in the last quarter. White Pine Capital LLC acquired a new position in shares of CryoPort in the third quarter worth about $539,000. Royce & Associates LP purchased a new position in shares of CryoPort in the third quarter worth approximately $7,073,000. Diversified Trust Co increased its position in shares of CryoPort by 3.4% in the third quarter. Diversified Trust Co now owns 19,769 shares of the company’s stock worth $344,000 after acquiring an additional 657 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its position in shares of CryoPort by 376.7% in the third quarter. Russell Investments Group Ltd. now owns 399,047 shares of the company’s stock worth $6,943,000 after acquiring an additional 315,343 shares in the last quarter. 92.90% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other CryoPort news, Director Daniel Hancock sold 74,379 shares of the company’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $20.21, for a total value of $1,503,199.59. Following the transaction, the director owned 69,052 shares of the company’s stock, valued at approximately $1,395,540.92. This represents a 51.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark W. Sawicki sold 10,000 shares of the stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $19.93, for a total value of $199,300.00. Following the sale, the insider owned 92,356 shares of the company’s stock, valued at $1,840,655.08. This trade represents a 9.77% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 9.50% of the company’s stock.

About CryoPort

Cryoport, Inc. provides temperature-controlled supply chain services for the life sciences industry. Its offerings support the development and commercial distribution of cell and gene therapies, biologics, reproductive medicine products and other temperature-sensitive materials. The company’s services include specialized shipping systems and packaging, transportation management, cryogenic storage, shipment monitoring and logistics support. These solutions are designed to help customers maintain required conditions and manage the handling of sensitive materials across clinical and commercial supply chains.